Abstract
Therapeutic targeting of pre-leukemic stem cells (pre-LSCs) may be a viable strategy to eradicate residual disease and prevent leukemia relapse. Now in Cell Stem Cell, Cai et al. (2015) show that loss-of-function mutations in RUNX1 reduce ribosome biogenesis and provide pre-LSCs a selective advantage over normal hematopoietic cells through increased stress resistance.
Original language | English (US) |
---|---|
Article number | 1816 |
Pages (from-to) | 129-131 |
Number of pages | 3 |
Journal | Cell Stem Cell |
Volume | 17 |
Issue number | 2 |
DOIs | |
State | Published - Aug 6 2015 |
ASJC Scopus subject areas
- Molecular Medicine
- Genetics
- Cell Biology